The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients

@article{Nomura2009TheEO,
  title={The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients},
  author={Shosaku Nomura and Norihito Inami and Akira Shouzu and Seitarou Omoto and Yutaka Kimura and Nobuyuki Takahashi and Atsushi Tanaka and Fumiaki Urase and Yasuhiro Maeda and Hajime Ohtani and Toshiji Iwasaka},
  journal={Platelets},
  year={2009},
  volume={20},
  pages={16 - 22}
}
Platelet-derived microparticles (PDMP) play an important role in the pathogenesis of diabetic vasculopathy, and statins or eicosapentaenoic acid (EPA) have been shown to have a beneficial effect on atherosclerosis in hyperlipidemic patients. However, the influence of EPA and statins on PDMP and adiponectin in atherosclerosis is poorly understood. We investigated the effect of pitavastatin and EPA on circulating levels of PDMP and adiponectin in hyperlipidemic patients with type II diabetes. A… Expand
Effects of sarpogrelate, eicosapentaenoic acid and pitavastatin on arterioslcerosis obliterans-related biomarkers in patients with type 2 diabetes (SAREPITASO study)
TLDR
It is suggested that combination therapy using pitavastatin and EPA possesses an antiatherosclerotic effect and may be beneficial for prevention of vascular complications in patients with T2DM. Expand
Differential Diabetogenic Effect of Pitavastatin and Rosuvastatin, in vitro and in vivo
TLDR
Pitavastatin showed lower diabetogenic effects than rosuvastatin in mice that may be mediated by minor attenuations in insulin signaling in adipocytes, which is reported to exert neutral effects on serum glucose level, but the precise mechanism is unknown. Expand
Effects of eicosapentaenoic acid on platelet function in patients taking long-term aspirin following coronary stent implantation.
TLDR
Investigation of the antiplatelet effect of EPA combined with acetylsalicylic acid following stent implantation found that EPA treatment had a potential to suppress collagen-induced platelet aggregation in patients with a high plasma EPA/AA ratio. Expand
Pleiotropic effects of pitavastatin
  • J. Davignon
  • Medicine
  • British journal of clinical pharmacology
  • 2012
TLDR
It is concluded that the diverse pleiotropic actions of pitavastatin may contribute to reducing cardiovascular morbidity and mortality beyond that achieved through LDL-C reduction. Expand
Pitavastatin in the Management of Hypercholesterolemia
TLDR
Pitavastatin has been reported to be associated with a lower frequency of adverse drug effects such as hepatic dysfunction and rhabdomyolysis, therefore, it may be judged as one of the safer among the strong statins. Expand
Pitavastatin: a review of its use in the management of hypercholesterolaemia or mixed dyslipidaemia.
TLDR
Pitavastatin appears to be an attractive alternative for the treatment of patients with primary hypercholesterolaemia or mixed dyslipidaemia who have not responded adequately to diet and other non-pharmacological measures, and may present a useful treatment option in patients requiring polypharmacy, such as those at high risk of cardiovascular disease. Expand
Pitavastatin: a New 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor for the treatment of hyperlipidemia
TLDR
Pitavastatin has not been shown to improve clinical outcomes in high-risk patient populations and thus may not be the agent of choice in many patients at this time in lieu of cheaper, clinically proven alternatives. Expand
Influence of different supplementation on platelet aggregation in patients with rheumatoid arthritis
TLDR
Omega-3 PUFAs are essential for health and are known to possess anti-inflammatory properties, improving cardiovascular health as well as benefiting inflammatory diseases and co-administration of supplementation-concentrated fish oil may reduce platelet aggregation in adults with RA. Expand
Are all statins the same? Focus on the efficacy and tolerability of pitavastatin.
  • P. M. da Silva
  • Medicine
  • American journal of cardiovascular drugs : drugs, devices, and other interventions
  • 2011
TLDR
Pitavastatin, the latest addition to the statin family, produces potent and consistent beneficial effects on lipids, is well tolerated, and has a favorable pharmacokinetic profile. Expand
Pitavastatin approved for treatment of primary hypercholesterolemia and combined dyslipidemia
  • J. Sasaki
  • Medicine
  • Vascular health and risk management
  • 2010
TLDR
The reported improvements in lipid profiles are consistent among the studies conducted in Japan, Korea, Thailand, and Europe, and are expected to establish its position for preventing and treating cardiovascular disease. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 67 REFERENCES
Effects of Pitavastatin on Adiponectin in Patients with Hyperlipidemia
TLDR
It is suggested that pitavastatin possesses an adiponectin-increasing effect in patients with hyperlipidemia and this effect is influenced by intensive platelet activation. Expand
Correlation between adiponectin and reduction of cell adhesion molecules after pitavastatin treatment in hyperlipidemic patients with type 2 diabetes mellitus.
TLDR
It is suggested that pitavastatin possesses an adiponectin-dependent anti-atherosclerotic effect in hyperlipidemic patients with type 2 diabetes in addition to its lowering effects on total cholesterol and LDL-C. Expand
Probucol and ticlopidine: effect on platelet and monocyte activation markers in hyperlipidemic patients with and without type 2 diabetes.
TLDR
Administration of probucol and ticlopidine to hyperlipidemic patients with type 2 diabetes may help to prevent the development of cardiovascular complications caused by modified LDL, selectins, or activated platelets and monocytes. Expand
Effects of eicosapentaenoic acid on platelet activation markers and cell adhesion molecules in hyperlipidemic patients with Type 2 diabetes mellitus.
TLDR
Findings suggest that in hyperlipidemic patients with Type 2 diabetes, EPA may prevent complications caused by oxidized LDL, E-selectin, and activated platelets or monocytes. Expand
Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia.
TLDR
Findings indicate a dose-dependent effect of the drug on TC and LDL-C concentrations, which were stable during long treatment of patients with heterozygous familial hypercholesterolemia. Expand
Platelet activation markers, microparticles and soluble adhesion molecules are elevated in patients with arteriosclerosis obliterans: therapeutic effects by cilostazol and potentiation by dipyridamole
TLDR
It is suggested that platelets are activated in ASO patients, and cilostazol is effective to reduce platelet activation, and dipyridamole may potentiate the beneficial effect of cilastazol inASO patients. Expand
Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis
TLDR
Testing the hypothesis that long-term use of eicosapentaenoic acid (EPA) is effective for prevention of major coronary events in hypercholesterolaemic patients in Japan who consume a large amount of fish found it to be a promising treatment. Expand
Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus.
TLDR
Results suggest that platelet-derived microparticles may participate in the development or progression of atherosclerosis in patients with diabetes mellitus. Expand
Effect of oral administration of highly purified eicosapentaenoic acid on platelet function, blood viscosity and red cell deformability in healthy human subjects.
TLDR
Reduction of platelet aggregation and improvement of the rheological properties of the erythrocyte might be explained by an increase in the EPA content in platelet and ery Throcyte phospholipids. Expand
Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Dose-finding study using the double-blind, three-group parallel comparison.
TLDR
Pitavastatin significantly decreased the serum levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) at doses of 1mg/day or more, and significant dose-dependence of the effect of this drug was observed within the dose range from 1 mg/ day to 4 mg/day. Expand
...
1
2
3
4
5
...